Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

NCT00664898
terminatedphase_2

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

NCT00529503
completedphase_2

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

NCT00435916
completedphase_1

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

NCT00655837
completedphase_1

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

NCT00525447
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00664898Phase 1

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT00529503Phase 2

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Terminated
NCT00435916Phase 2

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Completed
NCT00655837Phase 1

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Completed
NCT00525447Phase 1

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Completed
NCT00556699Phase 1

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6